Taconic Capital Advisors LP Biogen Inc. Transaction History

Taconic Capital Advisors LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	BUY	$282.99 - $369.05 $27.5 Million - $35.8 Million	97,000 Added 485.0%	117,000 $33.1 Million
Q2 2021 Aug 16, 2021	BUY	$259.0 - $414.71 $1.3 Million - $2.07 Million	5,000 Added 33.33%	20,000 $6.93 Million
Q1 2021 May 17, 2021	BUY	$242.95 - $284.63 $1.21 Million - $1.42 Million	5,000 Added 50.0%	15,000 $4.2 Million
Q4 2020 Feb 16, 2021	SELL	$236.26 - $355.63 $9.45 Million - $14.2 Million	-40,000 Reduced 80.0%	10,000 $2.45 Million
Q3 2020 Nov 16, 2020	BUY	$264.77 - $305.71 $3.97 Million - $4.59 Million	15,000 Added 42.86%	50,000 $14.2 Million
Q2 2020 Aug 14, 2020	SELL	$258.66 - $342.55 $5.04 Million - $6.68 Million	-19,500 Reduced 35.78%	35,000 $9.36 Million
Q1 2020 May 15, 2020	BUY	$268.85 - $341.04 $6.59 Million - $8.36 Million	24,500 Added 81.67%	54,500 $17.2 Million
Q4 2019 Feb 14, 2020	SELL	$220.06 - $304.07 $1.1 Million - $1.52 Million	-5,000 Reduced 14.29%	30,000 $8.9 Million
Q2 2019 Aug 14, 2019	BUY	$219.29 - $241.72 $7.68 Million - $8.46 Million	35,000 New	35,000 $8.19 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Taconic Capital Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Taconic Capital Advisors LP with notifications on news.